PMC:7228307 / 224-637 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"21","span":{"begin":359,"end":363},"obj":"Gene"}],"attributes":[{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ith antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. Thi"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":22,"end":36},"obj":"Body_part"},{"id":"T3","span":{"begin":37,"end":42},"obj":"Body_part"},{"id":"T4","span":{"begin":38,"end":40},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"ith antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. Thi"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":59,"end":67},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T8","span":{"begin":81,"end":82},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T9","span":{"begin":359,"end":361},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"ith antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. Thi"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":4,"end":11},"obj":"Chemical"},{"id":"T2","span":{"begin":43,"end":50},"obj":"Chemical"},{"id":"T3","span":{"begin":132,"end":140},"obj":"Chemical"},{"id":"T4","span":{"begin":373,"end":381},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_52214"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"ith antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. Thi"}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T1","span":{"begin":22,"end":36},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T2","span":{"begin":38,"end":40},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A1","pred":"meddra_id","subj":"T1","obj":"http://purl.bioontology.org/ontology/MEDDRA/10021496"},{"id":"A2","pred":"meddra_id","subj":"T2","obj":"http://purl.bioontology.org/ontology/MEDDRA/10021496"}],"text":"ith antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. Thi"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T2","span":{"begin":116,"end":120},"obj":"http://purl.obolibrary.org/obo/IDO_0000531"},{"id":"T3","span":{"begin":141,"end":150},"obj":"http://purl.obolibrary.org/obo/BFO_0000034"},{"id":"T4","span":{"begin":213,"end":222},"obj":"http://purl.obolibrary.org/obo/IDO_0000528"}],"text":"ith antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. Thi"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"21","span":{"begin":359,"end":363},"obj":"Gene"}],"attributes":[{"id":"A21","pred":"pubann:denotes","subj":"21","obj":"Gene:2213"}],"text":"ith antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. Thi"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T7","span":{"begin":224,"end":409},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ith antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. Thi"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T2","span":{"begin":22,"end":36},"obj":"Body_part"},{"id":"T3","span":{"begin":37,"end":42},"obj":"Body_part"},{"id":"T4","span":{"begin":38,"end":40},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"ith antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. Thi"}

{"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":224,"end":409},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ith antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. Thi"}